CDC7 and small cell lung carcinoma: In vivo treatments of the T-SCLC PDX Lx1042 (CDC7 H-score: 250) and NEPC PDX LuCap49 (CDC7 H-score: 210) likewise demonstrated sensitivity to the cisplatin and simurosertib combination, outperforming response to any single agent, and to the clinically relevant combination of cisplatin and etoposide, with T/C values at control experimental endpoint of 36% vs 59% for Lx1042, and of 14% vs 59% for LuCap49, respectively (Fig. 6e).